MCID: BRC012
MIFTS: 71

Brucellosis

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Brucellosis

MalaCards integrated aliases for Brucellosis:

Name: Brucellosis 12 77 54 60 56 45 15 17 74 3
Undulant Fever 12 54 3
Mediterranean Fever 12 77
Gibraltar Fever 12 54
Malta Fever 12 54
Bang's Disease 12
Maltese Fever 12
Cyprus Fever 54
Rock Fever 54

Characteristics:

Orphanet epidemiological data:

60
brucellosis
Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 60  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11077
ICD9CM 36 023 023.9
MeSH 45 D002006
NCIt 51 C84602
SNOMED-CT 69 75702008
MESH via Orphanet 46 D002006
ICD10 via Orphanet 35 A23.0 A23.1 A23.2 more
UMLS via Orphanet 75 C0006309
Orphanet 60 ORPHA1304
UMLS 74 C0006309

Summaries for Brucellosis

NIH Rare Diseases : 54 Brucellosis is a bacterial infection that spreads from animals to people via unpasteurized dairy products or by exposure to contaminated animal products or infected animals. Animals that are most commonly infected include sheep, cattle, goats, pigs, and dogs. Brucellosis can cause of range of signs and symptoms, some of which may persist or recur. Initial symptoms may include fever, sweats, malaise, anorexia, headache, fatigue, and/or pain in the muscles, joints, and/or back. Symptoms that may persist or recur include fevers, arthritis, swelling of the testicle and scrotum, swelling of the heart (endocarditis), neurologic symptoms (in up to 5% of cases), chronic fatigue, depression, and/or swelling of the liver or spleen. People who are in jobs or settings that increase exposure to the bacteria are at increased risk for infection. Antibiotics are used to treat brucellosis. Recovery may take a few weeks to several months, and relapses are common. Death from brucellosis is rare, occurring in no more than 2% of cases.

MalaCards based summary : Brucellosis, also known as undulant fever, is related to amyloidosis aa and purpura, and has symptoms including fever, fatigue and back pain. An important gene associated with Brucellosis is MEFV (MEFV Innate Immuity Regulator, Pyrin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Mycophenolic acid and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include testes, heart and breast, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A primary bacterial infectious disease that is caused by the bacteria of the genus Brucella, when humans come in contact with contaminated animals or animal products or ingestion of infected food products. The disease has symptom fever, has symptom sweat, has symptom headache, has symptom back pain, has symptom physical weakness, has symptom joint pain and has symptom fatigue.

Wikipedia : 77 Brucellosis is a highly contagious zoonosis caused by ingestion of unpasteurized milk or undercooked... more...

Related Diseases for Brucellosis

Diseases related to Brucellosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 687)
# Related Disease Score Top Affiliating Genes
1 amyloidosis aa 32.0 CRP MEFV SAA1
2 purpura 30.7 CRP IL6 TNF
3 crohn's disease 30.6 CRP IL10 SLC11A1 TNF
4 polyarteritis nodosa 30.6 CRP IL6 MEFV
5 q fever 30.5 IFNG IL10 IL4 IL6 TLR4 TNF
6 end stage renal failure 30.5 CRP IL6 TNF
7 proliferative glomerulonephritis 30.4 IFNG IL4 IL6
8 relapsing polychondritis 30.4 CRP IFNG IL6
9 leptospirosis 30.3 CRP CXCL8 IFNG IL10 IL6 TNF
10 endocarditis 30.3 CRP CXCL8 IL10 IL6 TNF
11 vasculitis 30.3 CRP MEFV TNF
12 cryopyrin-associated periodic syndrome 30.2 CRP IL1RN IL6
13 drug reaction with eosinophilia and systemic symptoms 30.2 CRP TNF
14 neuritis 30.2 IFNG IL4 TNF
15 scleritis 30.2 IFNG IL4 TNF
16 campylobacteriosis 30.1 IFNG SLC11A1 TLR4
17 hyper-igd syndrome 30.1 CRP IL1RN SAA1
18 ischemic heart disease 30.1 CRP IL6 TNF
19 myelitis 30.1 IL17A IL6 TNF
20 hemorrhagic fever 30.1 IFNG IL10 IL6 TNF
21 toxoplasmosis 30.1 IFNG IL10 IL4 IL6 TLR4 TNF
22 extrapulmonary tuberculosis 30.0 IFNG IL10 IL1RN SLC11A1
23 arteries, anomalies of 30.0 CRP IL6 TNF
24 capillary leak syndrome 30.0 CXCL8 IL2 IL6
25 crohn's colitis 30.0 CXCL8 IFNG IL2 TNF
26 acute respiratory distress syndrome 30.0 CXCL8 IL6 TNF
27 tuberculous peritonitis 30.0 CRP IFNG TNF
28 hepatitis a 30.0 IFNG IL10 TNF
29 septic arthritis 29.9 CRP CXCL8 TLR4
30 bacteriuria 29.9 CXCL8 IL6 TLR4
31 spondyloarthropathy 29.9 IFNG IL10 IL17A IL4 IL6 TNF
32 relapsing fever 29.9 CRP MEFV TNF
33 infective endocarditis 29.9 CRP IL6 TNF
34 human immunodeficiency virus infectious disease 29.9 IFNG IL10 IL2 IL6 TNF
35 salmonellosis 29.9 IFNG IL18 SLC11A1 TLR4
36 aseptic meningitis 29.9 CXCL8 IFNG IL10 IL1RN TNF
37 meningitis 29.9 CRP CXCL8 IFNG IL10 IL6 TNF
38 rheumatic fever 29.9 IL10 IL2 IL6 TNF
39 myocardial infarction 29.9 CRP IL10 IL6 TLR4 TNF
40 spondylitis 29.9 CRP IL17A IL1RN IL6 TNF
41 atherosclerosis susceptibility 29.8 CRP IL6 TLR4 TNF
42 acute pancreatitis 29.8 CRP CXCL8 IL10 IL18 IL6
43 poliomyelitis 29.8 IFNG IL10 IL4 TNF
44 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 29.8 IFNG IL10 IL17A
45 rheumatic heart disease 29.8 IL10 IL4 IL6 TNF
46 panuveitis 29.8 IL10 IL17A TNF
47 sleep apnea 29.8 CRP CXCL8 IL6 TNF
48 heart disease 29.8 CRP CXCL8 IL10 IL6 TNF
49 fasciitis 29.8 CXCL8 IL18 IL6 TNF
50 cysticercosis 29.8 IL18 IL6 TLR4

Graphical network of the top 20 diseases related to Brucellosis:



Diseases related to Brucellosis

Symptoms & Phenotypes for Brucellosis

Symptoms:

12
  • fever
  • fatigue
  • back pain
  • headache
  • joint pain
  • sweat
  • physical weakness

GenomeRNAi Phenotypes related to Brucellosis according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 CXCL8 IL10 IL17A IL18 IL2 IL2RA
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 CXCL8 IL10 IL17A IL18 IL2 IL2RA

MGI Mouse Phenotypes related to Brucellosis:

47 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.32 CRP IFNG IL10 IL17A IL18 IL1RN
2 hematopoietic system MP:0005397 10.31 IFNG IL10 IL17A IL18 IL1RN IL2
3 immune system MP:0005387 10.3 CRP IFNG IL10 IL17A IL18 IL1RN
4 growth/size/body region MP:0005378 10.29 IFNG IL10 IL17A IL18 IL1RN IL2
5 digestive/alimentary MP:0005381 10.28 IFNG IL10 IL17A IL18 IL2 IL2RA
6 cellular MP:0005384 10.25 IFNG IL10 IL18 IL1RN IL2 IL4
7 cardiovascular system MP:0005385 10.21 CRP IFNG IL10 IL18 IL1RN IL2
8 mortality/aging MP:0010768 10.18 IFNG IL10 IL17A IL18 IL1RN IL2
9 endocrine/exocrine gland MP:0005379 10.13 IFNG IL10 IL17A IL2 IL2RA IL4
10 integument MP:0010771 10.09 IFNG IL10 IL18 IL1RN IL4 IL6
11 liver/biliary system MP:0005370 10.01 IFNG IL10 IL2 IL4 IL6 MEFV
12 reproductive system MP:0005389 9.91 IFNG IL10 IL1RN IL2 IL4 IL6
13 neoplasm MP:0002006 9.87 IFNG IL10 IL2 IL6 SLC11A1 TLR4
14 respiratory system MP:0005388 9.81 IFNG IL10 IL17A IL2 IL2RA IL4
15 skeleton MP:0005390 9.61 IFNG IL10 IL17A IL1RN IL4 IL6
16 vision/eye MP:0005391 9.28 IFNG IL10 IL18 IL2 IL2RA IL4

Drugs & Therapeutics for Brucellosis

Drugs for Brucellosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 842)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 4 24280-93-1 446541
2
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492 6473866
3
Abatacept Approved Phase 4 332348-12-6 10237
4
Atenolol Approved Phase 4,Not Applicable 29122-68-7 2249
5
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
6
Naloxone Approved, Vet_approved Phase 4,Not Applicable 465-65-6 5284596
7
Tocopherol Approved, Investigational Phase 4,Phase 2,Phase 3 1406-66-2 14986
8
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
9
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
10
Cobicistat Approved Phase 4 1004316-88-4
11
Colchicine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-86-8 6167 2833
12
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 62-31-7, 51-61-6 681
13
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
14
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
15
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
16
Maraviroc Approved, Investigational Phase 4,Phase 2,Phase 3 376348-65-1 3002977
17
Daptomycin Approved, Investigational Phase 4 103060-53-3 16129629
18
Telavancin Approved Phase 4 372151-71-8
19
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
20
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
21
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
22
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
23
Adenosine Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 58-61-7 60961
24
Regadenoson Approved, Investigational Phase 4,Not Applicable 313348-27-5 219024
25
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 1 616-91-1 12035
26
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
27
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
28
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
29
Vancomycin Approved Phase 4,Phase 3 1404-90-6 441141 14969
30
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6 32051
31
Donepezil Approved Phase 4 120014-06-4 3152
32
Citalopram Approved Phase 4,Phase 3,Phase 2,Not Applicable 59729-33-8 2771
33
Norepinephrine Approved Phase 4,Phase 2 51-41-2 439260
34
Memantine Approved, Investigational Phase 4 19982-08-2 4054
35
Febuxostat Approved Phase 4,Phase 2 144060-53-7 134018
36 Nutmeg Approved Phase 4
37
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
38
Artesunate Approved, Investigational Phase 4,Phase 3 88495-63-0 5464098 6917864
39
Amodiaquine Approved, Investigational Phase 4,Phase 3 86-42-0 2165
40
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 26757 5195
41
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
42
Dapsone Approved, Investigational Phase 4 80-08-0 2955
43
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
44
Ibuprofen Approved Phase 4,Not Applicable 15687-27-1 3672
45
Naproxen Approved, Vet_approved Phase 4,Phase 2 22204-53-1 156391 1302
46
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
47
Ramipril Approved Phase 4 87333-19-5 5362129
48
Telmisartan Approved, Investigational Phase 4,Phase 3 144701-48-4 65999
49
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2 93-14-1 3516
50
Insulin Aspart Approved Phase 4,Phase 2 116094-23-6 16132418

Interventional clinical trials:

(show top 50) (show all 1062)
# Name Status NCT ID Phase Drugs
1 VeinViewer Assisted Intravenous Catheter Placement in the Pediatric Emergency Department Unknown status NCT00468065 Phase 4
2 Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression Unknown status NCT01875224 Phase 4 Belatacept;Tacrolimus
3 Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina. Unknown status NCT01397994 Phase 4 Nicorandil;Atenolol
4 Injection Assistance Device Versus Manual Injections for Delivery of Dermal Fillers Unknown status NCT01492140 Phase 4
5 Nasal Naloxone for Narcotic Overdose Unknown status NCT01912573 Phase 4 Intranasal (IN) naloxone;Intravenous (IV) naloxone;Intramuscular (IM) naloxone;Intraosseus (IO) naloxone
6 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
7 A Prospective Study of the InterFuse T(tm), Unknown status NCT02678130 Phase 4
8 Sleep and Cognition After Atripla to Stribild Switch Unknown status NCT02283060 Phase 4 Stribild;Atripla
9 The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMF Completed NCT02602028 Phase 4 colchicine
10 A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac) Completed NCT01449006 Phase 4 Maraviroc
11 Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD) Completed NCT00663403 Phase 4 Daptomycin
12 Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation Completed NCT00578968 Phase 4 Tiotropium;Placebo
13 Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5 Completed NCT02392208 Phase 4 Telavancin
14 Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients Completed NCT01435174 Phase 4 Ranolazine
15 Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD) Completed NCT01048879 Phase 4
16 Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis Completed NCT00877370 Phase 4 ertapenem
17 The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems Completed NCT00988117 Phase 4 Rivastigmine Patch 9.5 cm2
18 Integrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET Completed NCT01109992 Phase 4 Exercise plus Regadenoson (Lexercise);Regadenoson (Lexiscan)
19 Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease Completed NCT02476526 Phase 4 Low Volume iso-osmolar non-ionic radio contrast medium;Acetylcysteine Inhalation;Sodium Bicarbonate Solution
20 Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS) Completed NCT00263393 Phase 4 ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin
21 Helping Those With Mental Illness Quit Smoking Completed NCT01783912 Phase 4 Nicotine Patch
22 Ankle Block Versus Popliteal Fossa Block as Primary Anesthesia for Forefoot Surgical Procedures Completed NCT01376960 Phase 4
23 ULTRA Study for Pacemaker Patients Completed NCT00133289 Phase 4
24 Effect of Age on Latanoprost 0.005% in Patients With Glaucoma Completed NCT00224289 Phase 4 Latanoprost 0.005%
25 Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas Completed NCT00295178 Phase 4 Daptomycin;Vancomycin
26 Chronic Insertional Achilles Tendonitis Treated With or Without Flexor Hallucis Longus Tendon Transfer Completed NCT00950053 Phase 4
27 Needle Length In Obese Insulin-Using Diabetic Subjects Completed NCT00541372 Phase 4
28 Antidepressant Medication Plus Donepezil for Treating Late-life Depression Completed NCT00177671 Phase 4 Escitalopram;Donepezil;Venlafaxine;Placebo;Duloxetine
29 World-wide Randomized Antibiotic Envelope Infection Prevention Trial Completed NCT02277990 Phase 4
30 Foot and Ankle Clinic Application for Liposomal Related Anesthetic Completed NCT02586077 Phase 4 Exparel
31 Comparative Performance of PureVision, Acuvue Oasys and O2Optix Completed NCT00640341 Phase 4
32 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
33 Safety and Acceptability of the PrePex™ Device for Male Circumcision in Zambia Completed NCT01844102 Phase 4
34 The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina Completed NCT01763996 Phase 4 Febuxostat;Febuxostat placebo
35 A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors Completed NCT02019264 Phase 4 APD356-Lorcaserin hydrochloride;Placebo
36 Study of Long-term Peg Intron vs. Colchicine in Non-responders. Completed NCT00179413 Phase 4 PEG -Intron;Colchicine
37 Restricting the Use of Artesunate Plus Amodiaquine Combination Therapy to Malaria Cases Confirmed by a Dipstick Test: A Cluster Randomised Control Trial Completed NCT00832754 Phase 4
38 Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression Completed NCT00531947 Phase 4 Selegiline Transdermal System;Placebo
39 Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo Completed NCT01308619 Phase 4 Doxycycline
40 Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency Completed NCT00243542 Phase 4 ACZONE Gel, 5%;Vehicle
41 Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen Completed NCT00346216 Phase 4 celecoxib;Ibuprofen;Naproxen
42 Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo. Completed NCT00153101 Phase 4 Telmisartan;Combination of Telmisartan and Ramipril;Ramipril
43 Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery Recruiting NCT03858231 Phase 4 Norco 5Mg-325Mg Tablet;Ibuprofen 600 mg;Acetaminophen 325Mg Tab
44 Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy Recruiting NCT03554486 Phase 4 Fiasp;Novolog
45 CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera Recruiting NCT03705585 Phase 4 Vivotif Typhoid Oral Vaccine;Vaxchora
46 A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis Recruiting NCT03573323 Phase 4 Ixekizumab;Guselkumab;Placebo
47 Randomised Evaluation of Sodium Dialysate Levels on Vascular Events Recruiting NCT02823821 Phase 4
48 A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE ) Recruiting NCT03518034 Phase 4 Testosterone;Placebo
49 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
50 INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure Recruiting NCT02787044 Phase 4

Search NIH Clinical Center for Brucellosis

Cochrane evidence based reviews: brucellosis

Genetic Tests for Brucellosis

Anatomical Context for Brucellosis

MalaCards organs/tissues related to Brucellosis:

42
Testes, Heart, Breast, Prostate, Liver, Brain, Bone

Publications for Brucellosis

Articles related to Brucellosis:

(show top 50) (show all 4134)
# Title Authors Year
1
Chronic inflammation in adult familial Mediterranean fever patients: underlying causes and association with amyloidosis. ( 30786810 )
2019
2
Atypical Familial Mediterranean Fever Complicated with Gastrointestinal Amyloidosis Diagnosed Due to Paroxysmal Arthralgia and Intractable Diarrhea, Successfully Treated with Tocilizumab. ( 30713308 )
2019
3
Mediterranean fever gene variants and colchicine therapy in periodic fever, aphthous stomatitis pharyngitis, adenitis syndrome in a Mediterranean region. ( 30887853 )
2019
4
Toll-like receptor 4 promoter polymorphisms in a familial mediterranean fever patient with asymptomatic bacteriuria. ( 30656032 )
2019
5
Brucellosis seroprevalence in dairy cattle in China during 2008-2018: A systematic review and meta-analysis. ( 30308207 )
2019
6
Knowledge, Attitudes and Practices Associated with Brucellosis among Small-Scale Goat Farmers in Thailand. ( 30350754 )
2019
7
Evaluation of the economic impact of brucellosis in domestic yaks of Tibet. ( 30365244 )
2019
8
Predictors of therapeutic failure among patients with acute brucellosis treated by dual therapy with doxycycline-rifampin. ( 30411836 )
2019
9
Fluorescence polarization assay: Diagnostic evaluation for porcine brucellosis. ( 30521866 )
2019
10
Brucellosis knowledge and preventive practices among herders in Western Mongolia. ( 30552740 )
2019
11
Human brucellosis caused by raw dairy products: A review on the occurrence, major risk factors and prevention. ( 30572264 )
2019
12
Correction to: Brucellosis seroprevalence in ovine and caprine flocks in China during 2000-2018: a systematic review and meta-analysis. ( 30616594 )
2019
13
The Pattern of Tpeak-Tend Interval and QTdis, and Pdis in Children with Brucellosis. ( 30624756 )
2019
14
Correction: Clinical features of 2041 human brucellosis cases in China. ( 30650152 )
2019
15
A systematic review and meta-analysis of the prevalence of osteoarticular brucellosis. ( 30657765 )
2019
16
Protective efficacy of an inactivated Brucella abortus vaccine candidate lysed by GI24 against brucellosis in Korean black goats. ( 30670904 )
2019
17
Reemergence of Human Brucellosis in Israel. ( 30685898 )
2019
18
Human Brucellosis in Israel - The Saga Continues. ( 30685907 )
2019
19
Brucellosis in an adult female from Fate Bell Rock Shelter, Lower Pecos, Texas (4000-1300 BP). ( 30710889 )
2019
20
Characterization and evolution of countries affected by bovine brucellosis (1996 - 2014). ( 30739391 )
2019
21
Clinical and serological approach to patients with brucellosis: A common diagnostic dilemma and a worldwide perspective. ( 30742950 )
2019
22
Emergency response to occupational brucellosis in a pharmaceutical manufacturing enterprise. ( 30767335 )
2019
23
A review of the immunopathogenesis of Brucellosis. ( 30773082 )
2019
24
Epidemiologic, clinical, and laboratory characteristics of childhood brucellosis : A study in an Iranian children's referral hospital. ( 30778882 )
2019
25
Osteoarticular manifestations of human brucellosis: A review. ( 30788222 )
2019
26
Neutrophils dampen adaptive immunity in brucellosis. ( 30804100 )
2019
27
When brucellosis met the Assessment of SpondyloArthritis international Society classification criteria for spondyloarthritis: a comparative study. ( 30806857 )
2019
28
The impact of expanded brucellosis surveillance in beef cattle on human brucellosis in Korea: an interrupted time-series analysis. ( 30819243 )
2019
29
Correction: Correction: Clinical features of 2041 human brucellosis cases in China. ( 30830949 )
2019
30
Emergency response to occupational brucellosis in a pharmaceutical manufacturing enterprise. ( 30839144 )
2019
31
Prevalence of caprine brucellosis on herds of toba communities in Villa Río Bermejito, Chaco, Argentina (October 2010). ( 30843366 )
2019
32
Brucellosis knowledge, attitudes and practices of a South African communal cattle keeper group. ( 30843408 )
2019
33
Use of Rifabutin as an Alternative Agent for Human Brucellosis: A Case Report. ( 30844788 )
2019
34
Risk factors for new bovine brucellosis infections in Colombian herds. ( 30845954 )
2019
35
The Prevalence of Brucellosis in Different Provinces of Iran during 2013-2015. ( 30847321 )
2019
36
Multiple Myeloma or Brucellosis: ACase Report. ( 30848218 )
2019
37
Association of IL-17 gene polymorphisms and susceptibility to brucellosis in Hamadan, western Iran. ( 30851127 )
2019
38
Overexpression of wbkF gene in Brucella abortus RB51WboA leads to increased O-polysaccharide expression and enhanced vaccine efficacy against B. abortus 2308, B. melitensis 16M, and B. suis 1330 in a murine brucellosis model. ( 30856219 )
2019
39
Bayesian evaluation of three serological tests for the diagnosis of bovine brucellosis in Bangladesh. ( 30869026 )
2019
40
Seroprevalence of Human Brucellosis in Wadi Al Dawaser region of Saudi Arabia. ( 30881410 )
2019
41
Attenuated Salmonella secreting Brucella protective antigens confer dual-faceted protection against brucellosis and salmonellosis in a mouse model. ( 30885303 )
2019
42
Brucellosis after dengue. ( 30895885 )
2019
43
Status and influencing factors of farmers' private investment in the prevention and control of sheep brucellosis in China: A cross-sectional study. ( 30908484 )
2019
44
Efficacy and safety of long-term treatment with intravenous colchicine for familial Mediterranean fever (FMF) refractory to oral colchicine. ( 30604205 )
2019
45
Colchicine-induced myoneuropathy with myotonia in a patient with familial Mediterranean fever. ( 30604339 )
2019
46
Correction to: Evaluation of the effects of miRNAs in familial Mediterranean fever. ( 30617595 )
2019
47
Utility of new red cell parameters for distinguishing functional iron deficiency from absolute iron deficiency in children with familial Mediterranean fever. ( 30624866 )
2019
48
The relation of novel cardiovascular risk parameters in patients with familial Mediterranean fever. ( 30643639 )
2019
49
Familial Mediterranean Fever. ( 30686512 )
2019
50
The application of precision medicine in diagnosing familial Mediterranean fever. ( 30698071 )
2019

Variations for Brucellosis

Expression for Brucellosis

Search GEO for disease gene expression data for Brucellosis.

Pathways for Brucellosis

Pathways related to Brucellosis according to GeneCards Suite gene sharing:

(show top 50) (show all 83)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 CRP CXCL8 IFNG IL10 IL17A IL18
2
Show member pathways
13.88 CXCL8 IL10 IL17A IL18 IL2 IL2RA
3
Show member pathways
13.76 CXCL8 IFNG IL10 IL17A IL18 IL1RN
4
Show member pathways
13.65 CXCL8 IFNG IL10 IL17A IL18 IL2
5
Show member pathways
13.52 CXCL8 IL10 IL17A IL18 IL2 IL2RA
6
Show member pathways
13.44 CXCL8 IFNG IL10 IL17A IL18 IL1RN
7
Show member pathways
13.42 CXCL8 IL10 IL17A IL18 IL2 IL2RA
8
Show member pathways
13.31 CXCL8 IFNG IL10 IL18 IL2 IL6
9
Show member pathways
13.22 IFNG IL2 IL2RA IL4 TLR4 TNF
10
Show member pathways
13.05 IL2 IL2RA IL4 IL6 TLR4 TNF
11
Show member pathways
13.01 CXCL8 IFNG IL10 IL17A IL18 IL2
12 12.94 CXCL8 IFNG IL2 IL2RA IL4 IL6
13
Show member pathways
12.91 CXCL8 IFNG IL18 IL6 SAA1 TLR4
14
Show member pathways
12.82 IL2 IL2RA IL4 IL6 TNF
15
Show member pathways
12.79 IFNG IL10 IL18 IL2 IL2RA IL4
16
Show member pathways
12.74 IFNG IL10 IL17A IL18 IL2 IL6
17 12.72 IFNG IL10 IL17A IL1RN IL2 IL2RA
18
Show member pathways
12.72 CXCL8 IFNG IL18 IL2 IL2RA IL4
19
Show member pathways
12.6 IFNG IL10 IL17A IL18 IL2 IL2RA
20
Show member pathways
12.59 IFNG IL10 IL17A IL2 IL4 IL6
21
Show member pathways
12.56 IFNG IL10 IL2 IL2RA IL4 IL6
22
Show member pathways
12.53 IFNG IL2 IL4 TNF
23
Show member pathways
12.5 CXCL8 IFNG IL17A IL4 IL6 TNF
24
Show member pathways
12.5 CRP IFNG IL2 IL4 IL6 SAA1
25
Show member pathways
12.43 CXCL8 IFNG IL6 TLR4 TNF
26
Show member pathways
12.4 IFNG IL10 IL4 TLR4 TNF
27 12.4 IFNG IL10 IL18 IL6 TLR4 TNF
28 12.39 IL2 IL2RA IL6 TNF
29
Show member pathways
12.37 CXCL8 IL18 IL1RN IL6 TNF
30
Show member pathways
12.35 CXCL8 IFNG IL4 IL6 TLR4 TNF
31
Show member pathways
12.33 CXCL8 IL6 TLR4 TNF
32 12.33 CXCL8 IL10 IL1RN IL6 TNF
33
Show member pathways
12.28 IL10 IL2 IL6 TNF
34 12.26 IFNG IL6 TLR4 TNF
35
Show member pathways
12.23 CXCL8 IFNG IL10 IL17A IL18 IL2
36
Show member pathways
12.21 IFNG IL4 IL6 TLR4 TNF
37 12.2 CXCL8 IFNG IL2 IL4 IL6 TLR4
38
Show member pathways
12.2 CXCL8 IFNG IL10 IL17A IL18 IL2
39 12.17 IFNG IL10 IL2 IL2RA IL4 IL6
40
Show member pathways
12.16 IFNG IL18 IL2 IL2RA IL4
41
Show member pathways
12.15 IFNG IL10 IL17A IL18 IL2 IL6
42 12.07 CXCL8 IFNG IL10 IL6 TLR4 TNF
43 12.06 CXCL8 IL10 IL17A IL18 IL4 IL6
44 12.05 IFNG IL10 IL2 IL2RA IL6
45 12.02 IL2RA IL4 IL6 TNF
46 12.01 CXCL8 IFNG IL18 IL6 TLR4
47 12 CXCL8 IL18 IL2 TLR4
48
Show member pathways
12 CXCL8 IL17A IL6 TLR4
49 12 CXCL8 IFNG IL17A IL18 IL6 TLR4
50 11.99 CXCL8 IFNG IL2 IL4 IL6

GO Terms for Brucellosis

Cellular components related to Brucellosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 CRP CXCL8 IFNG IL10 IL17A IL18
2 extracellular space GO:0005615 9.4 CRP CXCL8 IFNG IL10 IL17A IL18
3 intracellular GO:0005622 9.16 IL1RN TLR4

Biological processes related to Brucellosis according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.97 CXCL8 IFNG IL10 IL17A IL18 IL1RN
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.96 IL18 IL6 TLR4 TNF
3 regulation of signaling receptor activity GO:0010469 9.96 CXCL8 IFNG IL10 IL17A IL18 IL1RN
4 positive regulation of DNA-binding transcription factor activity GO:0051091 9.92 IL10 IL6 TNF
5 positive regulation of gene expression GO:0010628 9.92 CRP IFNG IL18 IL4 IL6 SLC11A1
6 defense response to Gram-positive bacterium GO:0050830 9.91 CRP IL6 TNF
7 defense response to Gram-negative bacterium GO:0050829 9.89 IL6 SLC11A1 TLR4
8 neutrophil chemotaxis GO:0030593 9.89 CXCL8 IL1RN SAA1
9 positive regulation of JNK cascade GO:0046330 9.89 IL1RN TLR4 TNF
10 positive regulation of inflammatory response GO:0050729 9.88 IL18 IL2 TLR4 TNF
11 negative regulation of inflammatory response GO:0050728 9.88 IL10 IL2 IL2RA MEFV SAA1
12 cellular response to lipopolysaccharide GO:0071222 9.88 CXCL8 IL10 IL1RN IL6 TLR4 TNF
13 humoral immune response GO:0006959 9.87 IFNG IL6 TNF
14 response to glucocorticoid GO:0051384 9.87 IL10 IL1RN IL6 TNF
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.86 IL18 IL6 TNF
16 positive regulation of T cell proliferation GO:0042102 9.86 IL2 IL2RA IL4 IL6
17 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.85 IL18 TLR4 TNF
18 positive regulation of interleukin-6 production GO:0032755 9.85 IL1RN IL6 TLR4 TNF
19 positive regulation of nitric oxide biosynthetic process GO:0045429 9.84 IFNG TLR4 TNF
20 positive regulation of B cell proliferation GO:0030890 9.83 IL2 IL4 TLR4
21 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 IFNG IL18 IL2 IL4 IL6
22 acute-phase response GO:0006953 9.81 CRP IL6 SAA1
23 lipopolysaccharide-mediated signaling pathway GO:0031663 9.81 IL18 TLR4 TNF
24 negative regulation of interleukin-6 production GO:0032715 9.8 IL10 TLR4 TNF
25 positive regulation of cytokine secretion GO:0050715 9.79 IL10 SAA1 TNF
26 positive regulation of activated T cell proliferation GO:0042104 9.79 IL18 IL2 IL2RA
27 positive regulation of osteoclast differentiation GO:0045672 9.78 IFNG IL17A TNF
28 positive regulation of chemokine production GO:0032722 9.77 IL6 TLR4 TNF
29 positive regulation of T cell differentiation GO:0045582 9.77 IL2 IL2RA IL4
30 positive regulation of interferon-gamma production GO:0032729 9.77 IL18 IL2 SLC11A1 TLR4 TNF
31 regulation of regulatory T cell differentiation GO:0045589 9.75 IFNG IL2 IL2RA
32 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.74 IFNG TNF
33 negative regulation of growth of symbiont in host GO:0044130 9.74 IL10 TNF
34 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.74 IL10 TNF
35 positive regulation of interleukin-17 production GO:0032740 9.74 IL18 IL2
36 regulation of protein secretion GO:0050708 9.74 SAA1 TNF
37 interferon-gamma production GO:0032609 9.73 IL18 TLR4
38 negative regulation of interleukin-12 production GO:0032695 9.73 IL10 MEFV
39 negative regulation of interleukin-17 production GO:0032700 9.73 IFNG TLR4
40 positive regulation of immunoglobulin secretion GO:0051024 9.73 IL2 IL6
41 response to molecule of bacterial origin GO:0002237 9.73 CXCL8 IL10
42 interleukin-2-mediated signaling pathway GO:0038110 9.72 IL2 IL2RA
43 macrophage activation GO:0042116 9.72 SLC11A1 TLR4
44 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.72 IL10 IL1RN
45 neutrophil activation GO:0042119 9.72 CXCL8 IL18
46 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.71 TLR4 TNF
47 positive regulation of isotype switching to IgG isotypes GO:0048304 9.71 IL2 IL4
48 negative regulation of lipid storage GO:0010888 9.71 CRP IL6 TNF
49 T-helper 1 type immune response GO:0042088 9.7 IL18 TLR4
50 endothelial cell apoptotic process GO:0072577 9.7 IL10 TNF

Molecular functions related to Brucellosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.32 CXCL8 IFNG IL10 IL17A IL18 IL1RN
2 growth factor activity GO:0008083 9.26 IL10 IL2 IL4 IL6
3 protein binding GO:0005515 10 CRP CXCL8 IFNG IL10 IL17A IL18

Sources for Brucellosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20